Takhzyro (lanadelumab-flyo) is a human plasma kallikrein inhibitor and blocks the protein called kallikrein. Kallikrein regulates bradykinin production, a chemical that leads to inflammation (swelling). Takhzyro is a monoclonal antibody approved in the U.S. to prevent hereditary angioedema (HAE) in patients 2 years and older.